Piramal Pharma [PPLPHARMA] vs Cipla [CIPLA] Detailed Stock Comparison

Piramal Pharma

NSE
Loading...

Cipla

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Piramal Pharma wins in 5 metrics, Cipla wins in 14 metrics, with 0 ties. Cipla appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricPiramal PharmaCiplaBetter
P/E Ratio (TTM)257.1622.33Cipla
Price-to-Book Ratio3.063.86Piramal Pharma
Debt-to-Equity Ratio59.771.40Cipla
PEG Ratio-34.462.19Piramal Pharma
EV/EBITDA22.9715.78Cipla
Profit Margin (TTM)1.07%19.62%Cipla
Operating Margin (TTM)-4.68%22.31%Cipla
EBITDA Margin (TTM)N/A22.31%N/A
Return on Equity1.12%16.85%Cipla
Return on Assets (TTM)0.58%14.10%Cipla
Free Cash Flow (TTM)$2.28B$34.57BCipla
Dividend Yield0.07%1.72%Cipla
1-Year Return-12.51%4.88%Cipla
Price-to-Sales Ratio (TTM)2.724.46Piramal Pharma
Enterprise Value$293.10B$1,118.64BCipla
EV/Revenue Ratio3.214.07Piramal Pharma
Gross Profit Margin (TTM)64.11%68.25%Cipla
Revenue per Share (TTM)$69$340Cipla
Earnings per Share (Diluted)$0.73$66.73Cipla
Beta (Stock Volatility)0.060.10Piramal Pharma
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Piramal Pharma vs Cipla Stock Performance Analysis

Loading Price Chart...

Piramal Pharma
Cipla
Piramal Pharma Stock Overview | Cipla Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Piramal Pharma-3.83%-4.00%1.23%-3.34%-13.90%-24.41%
Cipla-0.56%-4.34%-5.71%0.18%-0.10%2.05%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Piramal Pharma-12.51%13.82%13.82%13.82%13.82%13.82%
Cipla4.88%35.41%95.30%138.29%366.24%893.49%

News Based Sentiment: Piramal Pharma vs Cipla

Piramal Pharma

News based Sentiment: MIXED

September presented a mixed bag for Piramal Pharma, with a potentially lucrative partnership announcement offset by disappointing financial results and concerning allegations. The conflicting signals from analysts and decreasing institutional holdings create a complex investment picture, making it a significant month for the company's trajectory.

View Piramal Pharma News Sentiment Analysis

Cipla

News based Sentiment: MIXED

Cipla delivered strong financial results in September, but these were tempered by a declining stock price, a leadership change, and emerging concerns about US tariffs. The mixed signals create both opportunities and risks for investors, making this a significant month for the company.

View Cipla News Sentiment Analysis

Performance & Financial Health Analysis: Piramal Pharma vs Cipla

MetricPPLPHARMACIPLA
Market Information
Market Cap i₹251.62B₹1.23T
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i3,726,8911,177,460
90 Day Avg. Volume i3,635,5291,203,818
Last Close₹187.73₹1,499.40
52 Week Range₹181.73 - ₹307.90₹1,335.00 - ₹1,607.80
% from 52W High-39.03%-6.74%
All-Time High₹307.90 (Nov 04, 2024)₹1,607.80 (Aug 25, 2025)
% from All-Time High-39.03%-6.74%
Growth Metrics
Quarterly Revenue Growth-0.01%0.03%
Quarterly Earnings Growth-0.01%0.10%
Financial Health
Profit Margin (TTM) i0.01%0.20%
Operating Margin (TTM) i-0.05%0.22%
Return on Equity (TTM) i0.01%0.17%
Debt to Equity (MRQ) i59.771.40
Cash & Liquidity
Book Value per Share (MRQ)₹61.35₹386.24
Cash per Share (MRQ)₹3.09₹131.44
Operating Cash Flow (TTM) i₹2.44B₹55.16B
Levered Free Cash Flow (TTM) i₹911.30M₹52.73B
Dividends
Last 12-Month Dividend Yield i0.07%1.72%
Last 12-Month Dividend i₹0.14₹26.00

Valuation & Enterprise Metrics Analysis: Piramal Pharma vs Cipla

MetricPPLPHARMACIPLA
Price Ratios
P/E Ratio (TTM) i257.1622.33
Forward P/E i42.1223.45
PEG Ratio i-34.462.19
Price to Sales (TTM) i2.724.46
Price to Book (MRQ) i3.063.86
Market Capitalization
Market Capitalization i₹251.62B₹1.23T
Enterprise Value i₹293.10B₹1.12T
Enterprise Value Metrics
Enterprise to Revenue i3.214.07
Enterprise to EBITDA i22.9715.78
Risk & Other Metrics
Beta i0.060.10
Book Value per Share (MRQ) i₹61.35₹386.24

Financial Statements Comparison: Piramal Pharma vs Cipla

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PPLPHARMACIPLA
Revenue/Sales i₹19.34B₹68.37B
Cost of Goods Sold i₹6.94B₹21.71B
Gross Profit i₹12.40B₹46.66B
Research & Development iN/AN/A
Operating Income (EBIT) i₹-905.80M₹15.25B
EBITDA i₹1.84B₹20.37B
Pre-Tax Income i₹-790.20M₹17.70B
Income Tax i₹26.80M₹4.78B
Net Income (Profit) i₹-817.00M₹12.92B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PPLPHARMACIPLA
Cash & Equivalents i₹3.69B₹5.89B
Total Current Assets i₹57.97B₹232.89B
Total Current Liabilities i₹37.66B₹54.84B
Long-Term Debt i₹33.13B₹2.52B
Total Shareholders Equity i₹81.25B₹312.89B
Retained Earnings i₹10.49B₹256.44B
Property, Plant & Equipment i₹250.60M₹52.62B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PPLPHARMACIPLA
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPPLPHARMACIPLA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i3,726,8911,177,460
Average Daily Volume (90 Day) i3,635,5291,203,818
Shares Outstanding i1.32B807.62M
Float Shares i599.16M562.88M
% Held by Insiders i0.55%0.31%
% Held by Institutions i0.21%0.41%

Dividend Analysis & Yield Comparison: Piramal Pharma vs Cipla

MetricPPLPHARMACIPLA
Last 12-Month Dividend i₹0.14₹26.00
Last 12-Month Dividend Yield i0.07%1.72%
3-Year Avg Annual Dividend i₹0.08₹16.00
3-Year Avg Dividend Yield i0.07%0.76%
3-Year Total Dividends i₹0.25₹48.00
Ex-Dividend DateJul 16, 2025Jun 27, 2025